September 29th, 2011
Meta-Analysis Explores Real World CV Risk of NSAIDs
Larry Husten, PHD
A new meta-analysis sheds additional light on the cardiovascular risk of NSAIDs as used in the real world, including low doses of the most popular drugs, over short periods, and in low-risk populations. In a paper published online in PLoS Medicine, Patricia McGettigan and David Henry analyzed data from 30 case-control studies including 184,946 CV events and […]
May 10th, 2011
Short-Term NSAID Use Linked to Increased CV Risk
Larry Husten, PHD
Short-term use of NSAIDs, including diclofenac, is associated with increased cardiovascular risk, according to a very large study published online in Circulation. Danish researchers used a national registry to study more than 83,000 patients who were admitted to the hospital for a first MI from 1997 to 2006. Some 42% of the patients received NSAIDs during […]
January 12th, 2011
Large Meta-Analysis Explores Cardiovascular Safety of NSAIDs
Larry Husten, PHD
A large network meta-analysis has found “little evidence” to suggest that any of the commonly used NSAIDs or COX 2 inhibitors are safe in terms of cardiovascular risk. In a paper published in BMJ, Sven Trelle and colleagues analyzed data from 31 trials in which patients receiving an NSAID were compared to another NSAID or placebo. Rofecoxib […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?